EU Laboratory Capability Monitoring System (EULabCap): Report on 2016 survey of EU/EEA country capabilities and capacities
This report for 2016, which presents the indicator results for EU and EEA (European Economic Area) countries, aims to help policymakers identify possible areas for action and to evaluate the impact of capacity strengthening activities and health system reforms.
Europe is steadily building more robust laboratory defences against epidemics and antimicrobial resistance threats.
ECDC’s report EU Laboratory Capability (EULabCap) published on the 30th of April, based on the results of the 2016 survey, concludes that the EU/EEA can rely in a public health microbiology system with strong overall capabilities and substantial capacity to fulfil EU surveillance and response.
Emerging spread of new fungal species poses risk for healthcare settings in the EU/EEA
The rise in Europe of Candida auris infections, a difficult-to-control fungus, is of concern. The fungus spreads easily in healthcare settings, can cause invasive infections, and is also associated with resistance to multiple classes of anti-fungal medication.
Rapid risk assessment: Candida auris in healthcare settings – Europe
This rapid risk assessment update appraises the risk for spread of C. auris in hospitals in the European Union and European Economic Area (EU/EEA) countries
External quality assessment scheme for Bordetella pertussis serology 2016
This external quality assessment (EQA) to assess the ability of national reference laboratories from EU/EEA Member States to correctly perform laboratory serodiagnostic tests for pertussis was a collaborative study organised from February to April 2016.
EU/EEA capacity for the surveillance of hepatitis B and C using molecular methods
In order to explore whether the current capacity for EU/EEA-wide molecular characterisation for surveillance of HBV and HCV is sufficient to be feasible and what gaps need to be addressed, a survey of EU/EEA Member States was conducted to assess their laboratory capacity and needs in relation to the molecular characterisation of hepatitis B and C.
European laboratories move forward towards stronger epidemic readiness for infectious disease threats.
The latest EULabCap data on assessing the public health laboratory capacities among 30 EU and EEA countries in 2016 reveal continuous improvement in reducing inequalities, with ten more countries reaching fair to high capability levels over the 4 years of monitoring.
ECDC ENLabCap consultation meeting with EU enlargement countries
Overall aim of this regional ENLabCap consultation workshop is to discuss the adjustments proposed to the current EULabCap tool and agree on those needed to adapt it for the EU enlargement countries.
Gap analysis on securing diphtheria diagnostic capacity and diphtheria antitoxin availability in the EU/EEA
This gap analysis demonstrated that there are significant gaps in diphtheria diagnostic capacity within the EU/EEA, with only six Member States fulfilling the minimum criteria in terms of surveillance, specialised laboratory diagnostics and expertise.
Strong engagement of national public health laboratories to respond to communicable disease outbreaks and improve monitoring of antimicrobial resistance in the European Union.
The EU Laboratory Capability (EULabCap) report published today,
on the results of the 2015 survey, concludes that the EU/EEA as a whole has a strong and improving public health microbiology system, with an average EULabCap score of 7.5 on a scale of 10, up from 6.9 in 2013 and 7.3 in 2014.